ADIPOQ and COVID-19: Studies have provided mechanistic evidence for the metabolic dysregulation in COVID-19, notably through insulin resistance involving adiponectin/leptin and proinflammatory alterations [51,52], which fits with our observations, along with the decreased food intake observed during the acute phase of human disease, i.e., as evidenced by the infected mice in our studies [52].